High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C

Iranian Red Crescent Medical Journal

Volumn 14, Issue 8, 2012, Pages 2-

  Moghaddam, Mostafa Alavi ^a   Zali, Mohammad Reza ^a   Andabili, Seyed Hossein Aalaei ^b   Derakhshan, Faramarz ^a   Miri, Seyed Mohammad ^b   Alavian, Seyed Moayed ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Demographic statistics; Hospitals; Pediatric; Personal and inter personal spaces

Indexed keywords

ALANINE AMINOTRANSFERASE; COPEGUSS; HEMOGLOBIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; GENOTYPE; HEMOPHILIA; HEPATITIS C; HUMAN; IRAN; LEUKOCYTE COUNT; LEUKOPENIA; RETINA HEMORRHAGE; SIDE EFFECT; THROMBOCYTE; VIROLOGY; WEIGHT REDUCTION;

EID: 84864592585     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med. 2008;6:66.
2. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int. 2010;30(8):1173-1180.
3. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 Suppl 1:74-81.
4. Ghosh K. Challenges of haemophilia care in India: Lest we forget. Indian J Med Res. 2010;130(1):87.
5. Samimi Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia. 2007;13(2):156-163.
6. Kalantari H, Mirzabaghi A, Akbari M, Shahshahan Z. Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients In Iran. Iran J Clin Infect Dis. 2011;6(2).
7. Karimi M, Ghavanini AA. Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap). 2001;31(3):251-255.
8. Keshvari M, Alavian SM, Behnava B, Miri SM, P KE, Tabatabaei SV, et al. Distribution of Hepatitis C Virus Genotypes in Iranian Patients with Congenital Bleeding Disorders. Iran Red Cres Med J. 2010;12(6):608-614.
9. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010;10(2):121-131.
10. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176-1184.
11. Shire NJ, Horn PS, Rouster SD, Stanford S, Eyster ME, Sherman KE. HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia. Hepatology. 2006;44(5):1146-1157.
12. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion. 2009;49(10):2195-2199.
13. Franchini M, Mengoli C, Veneri D, Mazzi R, Lippi G, Cruciani M. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis. J Antimicrob Chemother. 2008;61(6):1191-1200.
14. Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, et al. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. Haematologica. 2006;91(10):1367-1371.
15. Posthouwer D, Fischer K, De Heusden N, Mauser-Bunschoten EP. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience. Haemophilia. 2007;13(1):98-103.
16. Posthouwer D, Yee TT, Makris M, Fischer K, Griffioen A, Van Veen JJ, et al. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost. 2007;5(8):1624-1629.
17. Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. Hepat Mon. 2011;11(5):386-388.
18. Alavian SM. Are the Real HCV Infection Features in Iranian Patients the Same As What Is Expected? Hepat Mon. 2005;5(1):3.
19. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426-1432.
20. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360(3):257-267.
21. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. J Clin Gastroenterol. 2010;44(2):140-145.
22. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. Hepatology. 2002;36(4 Pt 1):967-972.
23. Rodriguez-Torres M, Rodriguez-Orengo JF, Rios-Bedoya CF, Fernandez-Carbia A, Gonzalez-Lassalle E, Salgado-Mercado R, et al. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. J Clin Virol. 2007;38(1):32-38.
24. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology. 1997;26(3 Suppl 1):112S-121S.
25. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(S1):S237-S244.